Deep Intelligent Pharma and Medrio, Inc. Announce Strategic Partnership to Build Next-Generation Smart Clinical Trial Sites

On March 19, 2019, VCBeat (WeChat Official Account: vcbeat) learned that Ms. Li Xing, Founder and CEO of Deep Intelligent Pharma, and Shinya Yamamoto, Managing Director of Asia Pacific at Medrio, Inc., announced a strategic partnership between Deep Intelligent Pharma and Medrio at the former’s Beijing office. The two parties declared they would apply cutting-edge AI technology to clinical trial data and operations, creating value for global pharmaceutical R&D clients in China, Japan, Australia, the United States, and Europe. This collaboration will enable highly complementary product offerings, leverage artificial intelligence to empower clinical trials, provide solutions on a global scale, and establish a next-generation network of intelligent clinical trial sites.

Since 2005, Medrio, as the world’s first innovative company to offer a cloud-based clinical trial system, has been building a true SaaS platform for data management in clinical trials. Its Electronic Data Capture (EDC) and electronic clinical tools are designed for complex clinical trials, delivering systems and services that are faster, more cost-effective, and smarter than those of its competitors. Currently, Medrio provides next-generation clinical trial systems to over 500 clients across more than 95 countries worldwide, covering sectors such as pharmaceuticals, medical devices, biotechnology, animal health, diagnostics, and Contract Research Organizations (CROs), and has cumulatively supported more than 3,000 clinical trial projects.

This collaboration marks the comprehensive entry of next-generation clinical trial data and operating systems, representing international first-class quality, into the Chinese market. As a leading innovator in the AI-driven new drug R&D sector, Deep Intelligent Pharma and Medrio will engage in extensive cooperation across areas such as the introduction of clinical trial technologies, market expansion, base development, and product integration and intelligentization. In the future, the two companies will jointly provide a fully modular, integrated clinical platform for the Chinese market, encompassing various clinical system tools including Medrio EDC, ePRO, eSource, and eConsent, thereby achieving a closed-loop data ecosystem.

The widespread adoption of electronic clinical tools, such as eSource, will reshape the entire industry landscape, comprehensively improve clinical trial data collection methods, effectively shorten the drug development cycle, make outstanding contributions to enhancing the quality of clinical trial data in China, and ultimately benefit patients. Furthermore, multiple AI platforms from Deep Intelligent Pharma, including DEEP-PV for pharmacovigilance, will seamlessly integrate with the Medrio system, enabling intelligent ecosystem expansion across its full product suite. This integration is dedicated to providing global partners with end-to-end solutions covering clinical trial data collection, analysis, management, and safety surveillance.

Deep Intelligent Pharma is currently collaborating with multiple clinical trial sites to prepare for the pilot launch of innovative, intelligent clinical trial centers. Selected sites will fully implement the “Deep Intelligent Pharma + Medrio” full-module solution, accelerating toward the goal of building next-generation smart clinical trial centers.

Green: DIP Partial Clinical Integrated System Ecosystem

Blue: Medrio System Ecosystem

Deep Intelligent Pharma, established in 2017, is a high-tech innovation company dedicated to empowering the entire new drug R&D process with artificial intelligence technology, helping global pharmaceutical companies and their service providers accelerate their transition towards intelligence. The team consists of AI experts from top internet companies and pharmaceutical R&D experts from multinational pharmaceutical enterprises. Deep Intelligent Pharma's self-developed AI intelligent systems and related services cover the full chain of new drug R&D, including drug discovery, organic synthesis, clinical trials, pharmacovigilance, registration applications, medical translation, and other stages. In September 2018, Deep Intelligent Pharma received an exclusive Series B investment of nearly $15 million from Sequoia Capital. Currently, it serves over 50 leading pharmaceutical and medical device companies, CROs, and third-party institutions worldwide.

Medrio is a leading eClinical technology provider for early-phase pharmaceutical, device, and diagnostic clinical trials. Founded in 2005, the company offers cloud-based EDC, eSource, eConsent, and ePRO solutions that are fast, flexible, and user-friendly for collecting and managing clinical data and patient-reported outcomes. Medrio provides clinical trial systems to research institutions across a broad range of therapeutic areas, achieving significant success in oncology, infectious diseases, and other fields. With extensive experience across all stages of research, Medrio leads the market in early-phase trials. The company serves more than 500 enterprises globally, with its headquarters in San Francisco and offices in multiple regions both domestically and internationally.